Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment with high-dose anthracycline chemotherapy did not show any difference in troponin T levels, a biomarker associated with heart damage, at one month after their last chemotherapy dose compared with those who did not take an ACE inhibitor, according to a study presented at the American College of Cardiology's Annual Scientific Session.

Related Keywords

Middlesbrough , Redcar And Cleveland , United Kingdom , David Austin , American College Of Cardiology , Care Research , American College Of Cardiology Annual Scientific Session , National Institute For Health , James Cook University Hospital , American College , Annual Scientific , South Tees , National Institute , Chemotherapy , Heart , Ace Inhibitors , Ngiotensin , Anthracycline , Anthracyclines , Biomarker , Breast Cancer , Dancer , Cancer Treatment , Ardiology , Nzyme , Heart Failure , Hodgkin Lymphoma , Hospital , Lymphoma , Muscle , Non Hodgkin Lymphoma , Troponin ,